Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Freya Meds vs LaSara Medical Group

By GLP-1 ScorecardUpdated

Freya MedsFactor scores not reassessed.
Site position #399

Higher score

LaSara Medical GroupFactor scores not reassessed.
Site position #485

Lower score

Score comparison

Freya Meds has the higher recorded score — 58.6/100 to 54.5/100.

Freya Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Freya Meds is a GLP-1 specialist offering compounded semaglutide ($250–$297/mo) and compounded tirzepatide ($332–$390/mo).

Before you choose

Before comparing the headline prices, the Freya Meds review and the LaSara Medical Group review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Freya Meds vs Oria Meds and iThriveMD vs LaSara Medical Group compare each of them with another graded program, and the list of alternatives to Freya Meds ranks the programs closest to Freya Meds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the SnagRx review covers one graded close to these two, at 57.9/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueFreya Meds +10
43
33
Dose & formulationEven
64
64
Clinical oversightFreya Meds +2
71
69
Labs & monitoringFreya Meds +7
60
53
FulfillmentLaSara Medical Group +4
62
66
Contract termsFreya Meds +8
55
47
Freya Meds · top barLaSara Medical Group · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricFreya MedsLaSara Medical Group
WeighScore58.6/10054.5/100
GradeCC
Site position#399#485
Semaglutide$297/mo (compounded)$289/mo (compounded)
Tirzepatide$390/mo (compounded)$399/mo (bundle, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Freya Meds

Site position #399 · C

Factor scores not reassessed.

Strengths

  • GLP-1 specialist — not a multi-category telehealth
  • Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
  • Both semaglutide and tirzepatide available
  • Multi-month discount on quarterly billing
  • Claims 450,000+ enrolled

What to consider

  • No visible LegitScript or PCAB accreditation
  • Above-average pricing ($250–$390/mo)
  • Compounded only — no brand-name options
  • Now serves 49 U.S. states (one state excluded; specific exclusion not named)
LaSara Medical Group

Site position #485 · C

Factor scores not reassessed.

Strengths

  • Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
  • National telehealth plus an in-person option in Southern California — uncommon hybrid model
  • Free initial consultation
  • Active promotional pricing (30% off sitewide at the time of review)
  • GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles

What to consider

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy partner not named
  • LegitScript certification status not confirmed
  • Per-state availability not listed despite the national-telehealth claim
  • Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard